Clinical trial
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating…
NCT00569127 · National Cancer Institute (NCI), NIH · Active, not recruiting
Key facts
| NCT number | NCT00569127 |
|---|---|
| Title | Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor |
| Official title | Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2 |
| Intervention type | Biological, Drug, Other |
| Interventions | Bevacizumab, Laboratory Biomarker Analysis, Octreotide Acetate, Recombinant Interferon Alfa-2b |
| Enrollment | 427 |
| Start date | Dec 1, 2007 |
| Primary completion | Jan 1, 2015 |
| Completion | Jan 31, 2026 |
| First posted | Dec 6, 2007 |
| Last update posted | Dec 5, 2025 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: